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Abstract
Introduction
The kidneys play a crucial role in the regulation of electrolytes and acid-base homeostasis.
Urinary Strong Ion Difference (SIDu = NaU + KU—ClU) represents an important aspect of
renal acid-base regulation. We evaluated the role of SIDu as a marker of renal dysfunction
in critically ill patients.
Materials and Methods
Patients admitted to the Medical Intensive Care Unit with a diagnosis of AKI for whom con-
comitant urinary samples available for SIDu calculation were retrospectively reviewed and
staged according to KDIGO criteria for 3 days from inclusion. Patients were classified as
Recovered (R-AKI) or Persistent-AKI (P-AKI) whether they exited KDIGO criteria within the
3-day observation period or not. A control group with normal renal function and normal
serum acid-base and electrolytes was prospectively recruited in order to identify reference
SIDu values.
Results
One-hundred-and-forty-three patients with a diagnosis of AKI were included: 77 with R-AKI,
and 66 with P-AKI. Thirty-six controls were recruited. Patients with P-AKI had more severe
renal dysfunction and higher mortality than patients with R-AKI (SCr 2.23(IQR:1.68–3.45)
and 1.81(IQR1.5–2.5) mg/dl respectively, p<0.001; 24-h UO 1297(950) and 2100(1094) ml
respectively, p = 0.003); 30-d mortality, 39% and 13% respectively; p<0.001). SIDu signifi-
cantly differed between groups, with rising values from controls to P-AKI groups (16.4(12),
30(24) and 47.3(21.5) mEq/l respectively, p<0.001).
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Discussion
SIDu may be a simple and inexpensive tool in AKI patients’ evaluation. Further research is
needed to evaluate the ability of SIDu to identify patients with renal dysfunction before
derangements in serum creatinine or urine output are observed.
Introduction
Despite increased awareness by clinicians, Acute Kidney Injury (AKI) remains a serious clinical
condition with high morbidity and mortality[1,2]. Current diagnostic criteria are based on
serum Creatinine (SCr) and urinary output (UO)[3,4,5,6]. However, a growing body of evi-
dence suggests that these markers may be insufficient in the timely identification of kidney
injury and may lead to delays in diagnosis and treatment[7,8,9].
The evidence for novel serum and urinary biomarkers of AKI in critically ill patients is lack-
ing [10,11,12,13,14]. Kidneys play a crucial role in the regulation of electrolytes and acid-base
homeostasis[15,16]. Urinary Anion Gap ([AGu = [Na+]u + [K+]u–[Cl–]u) is traditionally
used in the diagnosis of hyperchloremic metabolic acidosis, namely in differentiating renal
from non renal causes. In the quantitative physicochemical approach to acid-base disorders
originally described by Stewart, AGu is replaced by the Urinary Strong Ion Difference (SIDu)
[17,18,19]. AGu and SIDu are mathematically equivalent. Hence, kidney dysfunction could be
manifested by the early inability to regulate acid-base disturbances caused by critical illness. In
patients with metabolic acidosis, impaired renal function was associated with greater SIDu
[20,21,22]. Furthermore, higher SIDu values were found in patients who developed AKI[23].
The aim of the present study was to investigate SIDu as a marker of renal dysfunction in
critically ill patients with AKI.
Materials and Methods
A retrospective study was conducted in the Medical Intensive Care Unit (MICU) of the Rhode
Island Hospital (Providence,RI, US). All patients admitted between September 2012 and Sep-
tember 2013 with a diagnosis of AKI according to KDIGO criteria, at any moment of their ICU
stay, and concomitant urinary samples available for SIDu calculation were reviewed. The
Rhode Island Hospital Institutional Review Board approved the study and waived the need for
informed written consent due to its retrospective nature. Patients’ records were anonymized
and de-identified prior to analysis.
For the purpose of the study we excluded patients with unbalanced acid-base and/or electro-
lytes homeostasis, hematuria, renal transplant, need for bladder irrigation, prior creation of a
neo-bladder, pregnancy, end stage renal disease, and age less than18 years. Patients were
included if serum and urine chemistries had been withdrawn within one hour of each other.
Patients demographics, diagnosis, severity scores (SAPS 2), 24-h UO, use of vasopressors,
loop diuretics, need for mechanical ventilation and renal replacement therapy (RRT) during
the observation period as well as ICU length-of-stay and 30-day mortality were recorded.
In order to identify normal SIDu values, a control group with normal renal function was
subsequently and prospectively recruited. All patients admitted between May and June 2015
with normal renal function defined by the lack of any criteria compatible with any KDIGO
stage were included. We excluded patients with hematuria, bladder irrigation, neo-bladder,
pregnancy, end stage renal disease, and age less than 18 years.
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AKI definition
Patients were staged according to KDIGO criteria. Baseline SCr was defined as the lowest SCr
in the previous 6 months, or if not available, the plasma creatinine nadir during the ICU stay.
Patients were staged according to both SCr and UO criteria (Table 1).
Day 0 was defined as the day when AKI was present and urinary biochemistry was available,
which did not necessarily correspond to AKI onset day. All AKI patients were followed and
staged according to KDIGO criteria for the next 3 days following inclusion. Controls were fol-
lowed for 1 day. Patients who no longer met KDIGO criteria within the 3-day observation
period were classified as Recovered-AKI (R-AKI); patients who still met KDIGO criteria within
this timeframe were classified as Persistent-AKI (P-AKI).
Laboratory measures
Recorded measures included arterial blood gases, serum lactate, serum urea, creatinine (SCr),
Na+, K+, Ca2+, Mg2+, Cl-, phosphate and albumin if available. Day-0 urinary Na+ (NaU), K+
(KU), Cl- (ClU) were recorded (urine analysis were performed on samples of the collecting
bags which were routinely emptied every 4 hours). Derived variables included:
• SIDu = NaU + KU − ClU;
• Plasmatic apparent SID (SIDa) = [Na+] + [K+] + [Ca2+] + [Mg2+] − [Cl−];
• Plasmatic effective SID (SIDe) = [HCO3−] + [albumin−] + [Pi−].
[Albumin-] and [Pi-] (mmol/L) were calculated from measured values and pH by the follow-
ing equations:
½albumin ¼ ½albuminð0:123 pH  0:631Þ
½Pi ¼ ½Pi ð0:309 pH  0:469Þ:
Statistical analysis
Data were analyzed with MedCalc (v12.2.1). Metric data were tested for normal distribution
with the Kolmogorov-Smirnov test. Results are expressed as mean and standard deviations
Table 1. KDIGO criteria for AKI diagnosis.
Stage Serum creatinine Urine Output
1 1.5–1.9 times baseline <0.5 ml/kg/h for 6–12 hours
OR
 0.3 mg/dl(26.5 μmol/L) increase
2 2.0–2.9 times baseline <0.5 ml/kg/h for 12 hours
3 3.0 times baseline < 0.3 ml/kg/h for 24 hours
OR OR
Increase in serum creatinine to 4.0 mg/dl(353.6 μmol/L) Anuria for 12 hours
OR
Initiation of RRT
(in patients <18 y, decrease in eGFR to <35ml/min/1.73m2)
Abbreviations: eGFR, estimated GFR; RRT, renal replacement therapy.
doi:10.1371/journal.pone.0156941.t001
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(SD), or median and interquartile range (IR) as appropriate. Data were compared using the t-
test or the Mann-Whitney U test where appropriate. Categorical variables were compared
using Chi-square or Fisher exact test. ANOVA or Kruskal Wallis test were used to compare
multiple means or medians respectively.
Receiver Operating Characteristic Curve (ROC) analysis was performed in order to assess
day-0 urinary Strong Ion Difference(SIDu) diagnostic performance to discriminate controls
(No-AKI) and P-AKI patients, and R-AKI and P-AKI patients respectively.
Patients enrollment in our retrospective study depended upon availability of simultaneous
serum and urine samples in AKI patients. We calculated, however, that this study had a 95%
power to detect a difference between means of 13.81 with a significance level (alpha) of 0.05
(two-tailed).
Results
One-hundred-and-forty-three patients with a diagnosis of AKI were included: 95 were males
(66%) and 48 females (34%). Mean age was 63 (16.3) yrs. Thirty-six control patients were
recruited. Patients' characteristics are summarized in Table 2.
Recovered vs persistent AKI
Seventy-seven (53%) patients were classified as R-AKI, while 66 (47%) patients as P-AKI. Base-
line SCr and SAPS2 score were higher in P-AKI than R-AKI group (p<0.05 and<0.05 respec-
tively). Patients with P-AKI required more diuretics, vasopressors and need for RRT than
R-AKI patients (p<0.05, 95% CI: 10.8–40.4; p<0.05, 95% CI: 5.1–34.4; p< 0.05, 95% CI: 3.8–
Table 2. Baseline characteristics between patients with Recovered (R-), Persistent (P-) AKI and Control Group.
R-AKI P-AKI Control p
Patient characteristics
Gender(M/F) 53/24 42/24 22/14 0.6
Age yrs(SD) 62.3(16.7) 63(15.9) 66.4(12.50 0.59
Baseline creatinine(mg/dl)(IQR) 0.92(0.75–1.12) 1.07(0.84–1.3) 0.78(0.5–0,8) <0.05*
SAPS 2 (SD) 40.4(12) 52.5(17) 29.5(14) <0.05*
Reason for ICU admission(%)
Acute respiratory failure 13(16) 8(12) 8(22) 0.65
Septic shock 21(27) 23(34) 3(8) 0.46
Cardiovascular failure 4(5) 2(3) 0(0 0.85
Liver Failure 3(4) 4(6) 0() 0.87
Hemorragic shock 8(10) 5(7) 0() 0.73
Neuro 1(1) 6(9) 4(11) 0.1
Other 27(35) 18(27) 21(58) 0.2
Treatments(%)
Vasoactive drugs 11(16) 23(34) 3(8) <0.05*
Renal Replacement Therapy 0(0) 8(12) 0() <0.05*
Diuretics 10(13) 26(39) 3(8) <0.05*
30-d mortality(%) 10(13) 26(39) 3(8) <0.05*
LOS-ICU days(IQR) 4(2–8) 4.5(2–13) 3(1–6) 0.51
Results reported as means(SD), medians(interquartile range) or n(%). SAPS 2, Simplified Acute Physiology Score 2. p values are for comparison across
the three groups.
* is for variables that differ statistically across groups of patients.
doi:10.1371/journal.pone.0156941.t002
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22.3 respectively). Mortality was higher in P-AKI group than R-AKI group (13% vs 39%
respectively; p<0.05; 95% CI: 11.9–41.3).
Renal function and SIDu
Patients with P-AKI had more severe renal dysfunction than patients with R-AKI: SCr values
were 1.81 (IQR:1.5–2.5) and 2.23 mg/dl(IQR:1.68–3.45) (p<0.001), while UO was 1297
(SD:950) ml and 2100(SD:1094) respectively (p = 0.003). R-AKI group showed less severe renal
dysfunction than P-AKI group according to KDIGO classification: KDIGO-1 and 2–3 were
diagnosed in 41 and 36 R-AKI patients respectively, whereas 20 KDIGO1 and 47 KDIGO2-3
patients were observed in the P-AKI group (OR 2.7, 95% CI 1.3–5.3, p = 0.004). SIDu values
significantly differed between R-AKI and P-AKI groups (p<0.0001). Plasmatic SIDa did not
differ between control, R-AKI and P-AKI patients (38.3(SD:3.2), 38.8(SD:6.8), and 38.2
(SD:4.9) mEq/l respectively; p = 0.9). On the contrary, SIDu significantly differed between
groups (16.4(SD:12), 30(SD:24) and 47.3(SD:21.5) mEq/l respectively), with rising values from
No-AKI to P-AKI groups (p<0.001) (Table 3) (Fig 1).
The diagnostic performance of Day-0 SIDu in discriminating controls and P-AKI patients
was excellent (AUC:0.9, 95% CI:0.83–0.95; p<0.0001) (Fig 2A). A cut-off of 30.8 mEq/l had
the highest sensitivity and specificity for the examined purpose (77% and 94% respectively).
The diagnostic performance of Day-0 SIDu in discriminating R-AKI and P-AKI patients was
fair (AUC: 0.7, 95% CI: 0.61–0.76; p<0.0001)(Fig 2B). A cut-off of 40 mEq/l had the highest
sensitivity and specificity for the examined purpose (72% and 60% respectively)
Discussion
Urinary output and blood biomarkers such as SCr are complementary tools in AKI evaluation.
However, their role has been questioned by many[13]. Recently, new emphasis has been placed
on urine and acid-base status in monitoring the decelopment of AKI[18,24]. In our study, we
evaluated SIDu values in patients with and without AKI. AKI patients were classified as having
R- or P-AKI. Although questioned by some authors, this temporal distinction has been shown
to have a prognostic validity[23,25], as it identifies two groups of patients with different renal
function and prognosis. Our results suggest that SIDu may be of prognostic value in patients
with AKI, as higher SIDu values were observed in patients with P-AKI. SIDu reflects the
Table 3. Day-0 renal function and Strong Ion Difference values of patients without acute kidney injury(Control Group), with reversible AKI(R-AKI)
and persistent AKI(P-AKI).
R-AKI P-AKI Controls p
Renal function
Urinary Output(ml/24h)(SD) 2100(1094) 1297(950) 2355(1380) 0.003*
Serum Creatinine(mg/dl)(IQR) 1.81(1.5–2.5) 2.23(1.68–3.45) 0.78(0.56–0.86) <0.001*
AKI stage(%)
Stage1 41(54) 20(30) 0 0.02*
Stage2 20(25) 23(34) 0 0.3
Stage3 16(20) 24(36) 0 0.05*
Strong ion difference (mEq/l)(SD)
SIDu 30(24) 47.3(21.5) 16.4(12) <0.001*
SIDa 38.8(6.8) 38.2(4.9) 38.3(3.2) 0.99
Results reported as means(SD), medians(interquartile range) or n(%).p values are for comparison across the three groups.
* is for variables that differ statistically across groups of patients.
doi:10.1371/journal.pone.0156941.t003
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physiologic drive for body fluid electroneutrality[15]. Little is known about the role of SIDu as
a marker of renal dysfunction, with most studies analyzing patients with renal dysfunction and
concomitant metabolic acidosis[20,21]. Kellum proposed that an adequate response to non-
renal metabolic acidosis should be a negative SIDu[19]. When a strong acid is added to plasma,
plasma SID decreases and metabolic acidosis results. In this setting, renal compensation is
marked by increases in NH4Cl excretion, which allows the elimination of Cl
- with a weak cat-
ion. Consequently, SIDu becomes negative, thus increasing the plasma SID with a
net alkalizing effect. Moviat et al. examined the plasma and urine chemistry in 65 critically ill
(mixed medical and surgical) patients with metabolic acidosis. They found that in patients with
metabolic acidosis, impaired renal function was associated with greater urinary SIDs[22].
In the present study, we evaluated SIDu values in AKI and controls. SIDu values differed
when compared to patients with normal renal function, with rising values from controls to
P-AKI groups. A similar behavior in SIDu values has been previously shown by Maciel et al.,
suggesting that alterations in NaU and ClU values may be viewed as part of AKI development
in critically ill patients[23]. In this setting, a defect of urine acidification seems to be character-
istic of AKI. In addition, day-0 SIDu diagnostic performance in discriminating controls and
P-AKI was excellent, while it performed less well in discriminating R-AKI and P-AKI groups.
This study has several limitations that deserve mention. First, this study is a retrospective
analysis that did not allow control of several variables and patients’ inclusion was dictated by
Fig 1. Boxplot representation of day-0 urinary Strong Ion Difference values across the three groups.
doi:10.1371/journal.pone.0156941.g001
Fig 2. A. Receiver Operating Characteristic curve for day-0 urinary Strong Ion Difference(SIDu) to
discriminate controls (no-AKI) and P-AKI patients.B. Receiver Operating Characteristic curve for day-0
urinary Strong Ion Difference(SIDu) to discriminate R-AKI and P-AKI patients.
doi:10.1371/journal.pone.0156941.g002
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the availability of urine samples for SIDu estimation. As a result, patients' inclusion did not
necessarily correspond to AKI onset, potentially grouping together patients by similar KDIGO
stage who were at different time points in AKI evolution.
Second, the study population was extremely heterogeneous. Different AKI causes and
pathophysiologic bases could have led to different urine biochemistry profiles. The small study
population precluded subgroup analysis.
Third, SIDu is one of the three independent variables that determine acid-base balance. Its
determination should be considered in light of other variables, such as pH, SIDa, SIDe, type
and SID of infused fluids. Available data did not allow us to analyze these variables, potentially
limiting the applicability of our finidngs.
Last, diuretic therapy is known to influence urine composition and acid-base status. As
such, loop diuretics increase Na+U and Cl-U concentrations and decrease SIDu in patients
with normal renal function, with a net alkalinizing effect[17,26]. Diuretic therapy could be a
confounding factor when interpreting urine electrolyte composition. However, as showed in
our population, the highest diuretic doses were administered to patients with the most severe
renal dysfunction and it is possible that diuretics might have had less impact on SIDu derange-
ments. This question remains to be specifically evaluated.
Conclusion
SIDu may be a promising, simple and inexpensive tool in the’ evaluation of patients with AKI.
Further research is needed to assess the utility of SIDu in the early detection of patients with
renal dysfunction prior to increases in serum creatinine or decreases in urine output.
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